This work aimed to analyze the 100 most-cited articles on antivascular endothelial growth factor (anti-VEGF) inhibitors.
Methods:
A literature search for anti-VEGF inhibitors using the Web of Science was completed using the bibliographic databases for peer-reviewed literature published in Ophthalmology, the New England Journal of Medicine, Journal of the American Medical Association, and Lancet. Primary outcomes were the most frequently cited articles and journals with the most citations as well as the specific drug and disease process studied.
Results:
There were 42 696 cumulative citations among the top 100 articles. The articles were published between 2004 to 2016, with most articles published in 2006. Ophthalmology published the greatest number of articles among the top 100 at 48, whereas the New England Journal of Medicine has the most citations per publication at 1714. Ranibizumab was the medication researched in most articles at 56, followed by bevacizumab at 48, aflibercept at 10, and pegaptanib at 9. Forty-two articles investigated treatment of age-related macular degeneration, followed by 24 investigating diabetic macular edema, 10 for retinal vein occlusion, 8 for proliferative diabetic retinopathy, 2 for retinopathy of prematurity and polypoidal choroidal vasculopathy, and 1 for corneal neovascularization.
Conclusions:
As evidenced by the considerable number of citations accumulated over the past 20 years, anti-VEGF inhibitors have led to significant research in ophthalmology.
KabbinavarFHurwitzHIFehrenbacherL, et al.Phase II, randomized trial comparing bevacizumab plus fluorouracil (Fu)/leucovorin (lv) with fu/lv alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21(1):60–65. doi:10.1200/jco.2003.10.066
4.
YangJCHaworthLSherryRM, et al.A randomized trial of bevacizumab, an anti–vascular endothelial growth factor antibody, for metastatic renal cancer. New Engl J Med. 2003;349(5):427–434. doi:10.1056/nejmoa021491
5.
VinoresSA. Pegaptanib in the treatment of wet, age-related macular degeneration. Int J Nanomedicine. 2006;1(3):263–268.
6.
JiangSParkCBarnerJC. Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab. J Clin Pharm Ther. 2014;39(3):234–239. doi:10.1111/jcpt.12146
7.
TremoladaGLattanzioRMazzolariGZerbiniG. The therapeutic potential of VEGF inhibition in diabetic microvascular complications. Am J Cardiovasc Drugs. 2007;7(6):393–398. doi:10.2165/00129784-200707060-00002
8.
CunninghamEAdamisAAielloL, et al.A phase II randomized double-masked trial of pegaptanib, an anti–vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112(10):1747–1757. doi:10.1016/j.ophtha.2005.06.007
9.
RosenfeldPJFungAEPuliafitoCA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36(4):336–339. doi:10.3928/1542-8877-20050701-15
10.
TravassosATeixeiraSFerreiraP, et al.Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg, Lasers. 2007;38(3):233–237. doi:10.3928/15428877-20070501-09
MongeonPPaul-HusA. The journal coverage of Web of Science and Scopus: a comparative analysis. Scientometrics. 2015;106(1):213–228. doi:10.1007/s11192-015-1765-5
14.
BoyerDSYoonYHBelfortR, et al.Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914. doi:10.1016/j.ophtha.2014.04.024
15.
BoyerDSFaberDGuptaS, et al.Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31(5):915–923. doi:10.1097/IAE.0b013e318206d18c
16.
FunatsuHNomaHMimuraTEguchiSHoriS. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116(1):73–79. doi:10.1016/j.ophtha.2008.09.037
17.
MandaiMWatanabeAKurimotoY, et al.Autologous induced stem-cell–derived retinal cells for macular degeneration. New Engl J Med. 2017;376(11):1038–1046. doi:10.1056/nejmoa1608368
18.
CarloWAFinerNNWalshMC, et al.Target ranges of oxygen saturation in extremely preterm infants. New Engl J Med. 2010;362(21):1959–1969. doi:10.1056/nejmoa0911781
19.
Kobrin KleinBE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14(4):179–183. doi:10.1080/09286580701396720
20.
YeungAWKAbdel-DaimMMAbushoukAIKadonosonoK. A literature analysis on anti-vascular endothelial growth factor therapy (anti-VEGF) using a bibliometric approach. Naunyn Schmiedebergs Arch Pharmacol. 2019;392(4):393–403. doi:10.1007/s00210-019-01629-y
21.
CarmelietP. Angiogenesis in health and disease. Nat Med. 2003;9(6):653–660. doi:10.1038/nm0603-653
GreenWR. Histopathology of age-related macular degeneration. Mol Vis. 1999;5:27.
24.
AlonTHemoIItinAPe’erJStoneJKeshetE. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1(10):1024–1028. doi:10.1038/nm1095-1024
25.
LamoreauxWJFitzgeraldMECReinerAHastyKACharlesST. Vascular endothelial growth factor increases release of gelatinase a and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res. 1998;55(1):29–42. doi:10.1006/mvre.1997.2056
26.
AsaharaTTakahashiTMasudaH, et al.VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18(14):3964–3972. doi:10.1093/emboj/18.14.3964
27.
HiratsukaSNakamuraKIwaiS, et al.MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell. 2002;2(4):289–300. doi:10.1016/s1535-6108(02)00153-8
28.
KimLAD’AmorePA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol. 2012;181(2):376–379. doi:10.1016/j.ajpath.2012.06.006
29.
RosenfeldPJMoshfeghiAAPuliafitoCA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers and Imaging. 2005;36(4):331–335. doi:10.3928/1542-8877-20050701-14
30.
DoggrellSA. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert Opin Pharmacother. 2005;6(8):1421–1423. doi:10.1517/14656566.6.8.1421
31.
GragoudasESAdamisAPCunninghamETFeinsodMGuyerDR. Pegaptanib for neovascular age-related macular degeneration. New Engl J Med. 2004;351(27):2805–2816. doi:10.1056/nejmoa042760
32.
RosenfeldPJBrownDMHeierJS, et al.Ranibizumab for neovascular age-related macular degeneration. New Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
33.
BrownDMKaiserPKMichelsM, et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New Engl J Med. 2006;355(14):1432–1444. doi:10.1056/nejmoa062655
34.
FerraraNDamicoLShamsNLowmanHKimR. Development of ranibizumab, an anti–vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26(8):859–870. doi:10.1097/01.iae.0000242842.14624.e7
35.
ChakravarthyUHardingSPRogersCA, et al.Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration. Ophthalmology. 2012;119(7):1399–1411. doi:10.1016/j.ophtha.2012.04.015
36.
HolashJDavisSPapadopoulosN, et al.VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393–11398. doi:10.1073/pnas.172398299
37.
HeierJSBrownDMChongV, et al.Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi:10.1016/j.ophtha.2012.09.006
38.
DugelPUKohAOguraY, et al.; HAWK and HARRIER Study Investigators. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84. doi:10.1016/j.ophtha.2019.04.017
39.
PożarowskaDPożarowskiP.The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. Cent Eur J Immunol. 2016;41(3):311–316. doi:10.5114/ceji.2016.63132
40.
AmbatiJFowlerBJ. Mechanisms of age-related macular degeneration. Neuron. 2012;75(1):26–39. doi:10.1016/j.neuron.2012.06.018
41.
MartinDFMaguireMGYingGS, et al.Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New Engl J Med. 2011;364(20):1897–1908. doi:10.1056/nejmoa1102673
42.
SengerDGalliSDvorakAPerruzziCHarveyVDvorakH. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983–985. doi:10.1126/science.6823562
43.
NguyenQDBrownDMMarcusDM, et al.Ranibizumab for diabetic macular edema. Ophthalmology. 2012;119(4):789–801. doi:10.1016/j.ophtha.2011.12.039
44.
ElmanMJAielloLPBeckRW, et al.Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077.e35. doi:10.1016/j.ophtha.2010.02.031
45.
MitchellPBandelloFSchmidt-ErfurthU, et al.; RESTORE Study Group. The RESTORE study. Ophthalmology. 2011;118(4):615–625. doi:10.1016/j.ophtha.2011.01.031
46.
BrownDMSchmidt-ErfurthUDoDV, et al.Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2015;122(10):2044–2052. doi:10.1016/j.ophtha.2015.06.017
47.
WellsJAGlassmanARAyalaAR, et al.Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New Engl J Med. 2015;372(13):1193–1203. doi:10.1056/nejmoa1414264
48.
VanderJF. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2012;2012:128–129. doi:10.1016/j.yoph.2012.03.030
49.
CampochiaroPAHeierJSFeinerL, et al.Ranibizumab for macular edema following branch retinal vein occlusion. Ophthalmology. 2010;117(6):1102–1112.e1. doi:10.1016/j.ophtha.2010.02.021.
50.
CampochiaroPAClarkWLBoyerDS, et al.Intravitreal aflibercept for macular edema following branch retinal vein occlusion. Ophthalmology. 2015;122(3):538–544. doi:10.1016/j.ophtha.2014.08.031
51.
BoyerDHeierJBrownDM, et al.Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion. Ophthalmology. 2012;119(5):1024–1032. doi:10.1016/j.ophtha.2012.01.042
52.
HolzFGRoiderJOguraY, et al.VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97(3):278–284. doi:10.1136/bjophthalmol-2012-301504
53.
Mintz-HittnerHAKennedyKAChuangAZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New Engl J Med. 2011;364(7):603–615. doi:10.1056/nejmoa1007374
54.
KohALeeWKChenLJ, et al.Everest study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453–1464. doi:10.1097/iae.0b013e31824f91e8
55.
ManzanoRPAPeymanGAKhanP, et al.Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol. 2006;91(6):804–807. doi:10.1136/bjo.2006.107912
56.
LinkerAYangARoperNWhitakerEKorensteinD. Impact of industry collaboration on randomised controlled trials in oncology. Eur J Cancer. 2017;72:71–77. doi:10.1016/j.ejca.2016.11.005
57.
RasmussenKBeroLRedbergRGøtzschePCLundhA. Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. BMJ. 2018;363:k3654. doi:10.1136/bmj.k3654
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
